Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus

Vaneet K Kalra, Vincent A. DeBari, Adel Zauk, Preetika Kataria, Dorothy Myridakis, Fuad Kiblawi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patent ductus arteriosus (PDA) is highly prevalent in pre-term neonates (PTN) and has been recognized as a neonatal co-morbidity. The purpose of this study was to determine if levels of brain (or B-type) natriuretic peptide (BNP), a peptide secreted by ventricular myocytes in response to volume or pressure overload, correlate with the size of the PDA. In a prospective design, 52 PTN (no PDA: n=24; PDA: n=28) were studied after obtaining parental consent. Those with genetic anomalies and congenital heart disease, except for PDA and patent foramen ovale, were excluded. Echocardiographic estimates offthe diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection the diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection for BNP assay. BNP levels in samples from PTN without PDA were 23.6 ng/L (median); 13.1 to 32.3 ng/L (IQR); initial samples (between days 3 and 7 of life) with small PDA (n=11), median 66.1 ng/L; 55.5 to 85.3 ng/L (IQR); with moderate PDA (n=6) median 284 ng/L; 204 to 622 ng/L (IQR); and with large PDA (n=11) 2410 ng/L median; 420 to 2770 ng/L (IQR). (p< 0.0001 for ANOVA; groupwise: p<0.05 for both no PDA vs. moderate and large PDA); Trend analysis suggested a strong association of BNP with size of PDA (p<0.001). Of 17 subjects with moderate to large PDA, pre and post-treatment (Ibuprofen; per standard protocol) data were obtained on 12 subjects. Pre-treatment BNP ranged from 111 to 5000 ng/L; post-treatment BNP decreased to 5.0 to 262 ng/L (p = 0.0005). Estimates of decision levels for treatment were made by examining dichotomized groups, i.e., no-tosmall vs. moderate-to-large and using receiver-operator characteristic (ROC) curve analysis yielding a value of 123 ng/L. BNP may obviate repeated echocardiography as follow up after treatment, or to monitor future course of respiratory distress secondary to PDA in PTN.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalAnnals of Clinical and Laboratory Science
Volume41
Issue number2
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Patent Ductus Arteriosus
Brain Natriuretic Peptide
Newborn Infant
Testing
Blood
Echocardiography
Ibuprofen
Analysis of variance (ANOVA)
Point-of-Care Testing
Assays
Brain
Association reactions
Peptides
Parental Consent
Therapeutics
Patent Foramen Ovale

Keywords

  • B-type natriuretic peptide
  • BNP
  • Neonates
  • Patent ductus arteriosus
  • Point of care testing
  • Premature infants

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Hematology
  • Medical Laboratory Technology
  • Microbiology
  • Molecular Biology
  • Clinical Biochemistry
  • Immunology

Cite this

Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. / Kalra, Vaneet K; DeBari, Vincent A.; Zauk, Adel; Kataria, Preetika; Myridakis, Dorothy; Kiblawi, Fuad.

In: Annals of Clinical and Laboratory Science, Vol. 41, No. 2, 01.03.2011, p. 131-137.

Research output: Contribution to journalArticle

Kalra, Vaneet K ; DeBari, Vincent A. ; Zauk, Adel ; Kataria, Preetika ; Myridakis, Dorothy ; Kiblawi, Fuad. / Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus. In: Annals of Clinical and Laboratory Science. 2011 ; Vol. 41, No. 2. pp. 131-137.
@article{b2fcbe68a9174140935de8fbb7dc1eb5,
title = "Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus",
abstract = "Patent ductus arteriosus (PDA) is highly prevalent in pre-term neonates (PTN) and has been recognized as a neonatal co-morbidity. The purpose of this study was to determine if levels of brain (or B-type) natriuretic peptide (BNP), a peptide secreted by ventricular myocytes in response to volume or pressure overload, correlate with the size of the PDA. In a prospective design, 52 PTN (no PDA: n=24; PDA: n=28) were studied after obtaining parental consent. Those with genetic anomalies and congenital heart disease, except for PDA and patent foramen ovale, were excluded. Echocardiographic estimates offthe diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection the diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection for BNP assay. BNP levels in samples from PTN without PDA were 23.6 ng/L (median); 13.1 to 32.3 ng/L (IQR); initial samples (between days 3 and 7 of life) with small PDA (n=11), median 66.1 ng/L; 55.5 to 85.3 ng/L (IQR); with moderate PDA (n=6) median 284 ng/L; 204 to 622 ng/L (IQR); and with large PDA (n=11) 2410 ng/L median; 420 to 2770 ng/L (IQR). (p< 0.0001 for ANOVA; groupwise: p<0.05 for both no PDA vs. moderate and large PDA); Trend analysis suggested a strong association of BNP with size of PDA (p<0.001). Of 17 subjects with moderate to large PDA, pre and post-treatment (Ibuprofen; per standard protocol) data were obtained on 12 subjects. Pre-treatment BNP ranged from 111 to 5000 ng/L; post-treatment BNP decreased to 5.0 to 262 ng/L (p = 0.0005). Estimates of decision levels for treatment were made by examining dichotomized groups, i.e., no-tosmall vs. moderate-to-large and using receiver-operator characteristic (ROC) curve analysis yielding a value of 123 ng/L. BNP may obviate repeated echocardiography as follow up after treatment, or to monitor future course of respiratory distress secondary to PDA in PTN.",
keywords = "B-type natriuretic peptide, BNP, Neonates, Patent ductus arteriosus, Point of care testing, Premature infants",
author = "Kalra, {Vaneet K} and DeBari, {Vincent A.} and Adel Zauk and Preetika Kataria and Dorothy Myridakis and Fuad Kiblawi",
year = "2011",
month = "3",
day = "1",
language = "English (US)",
volume = "41",
pages = "131--137",
journal = "Annals of Clinical and Laboratory Science",
issn = "0091-7370",
publisher = "Association of Clinical Scientists",
number = "2",

}

TY - JOUR

T1 - Point-of-care testing for B-type natriuretic peptide in premature neonates with patent ductus arteriosus

AU - Kalra, Vaneet K

AU - DeBari, Vincent A.

AU - Zauk, Adel

AU - Kataria, Preetika

AU - Myridakis, Dorothy

AU - Kiblawi, Fuad

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Patent ductus arteriosus (PDA) is highly prevalent in pre-term neonates (PTN) and has been recognized as a neonatal co-morbidity. The purpose of this study was to determine if levels of brain (or B-type) natriuretic peptide (BNP), a peptide secreted by ventricular myocytes in response to volume or pressure overload, correlate with the size of the PDA. In a prospective design, 52 PTN (no PDA: n=24; PDA: n=28) were studied after obtaining parental consent. Those with genetic anomalies and congenital heart disease, except for PDA and patent foramen ovale, were excluded. Echocardiographic estimates offthe diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection the diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection for BNP assay. BNP levels in samples from PTN without PDA were 23.6 ng/L (median); 13.1 to 32.3 ng/L (IQR); initial samples (between days 3 and 7 of life) with small PDA (n=11), median 66.1 ng/L; 55.5 to 85.3 ng/L (IQR); with moderate PDA (n=6) median 284 ng/L; 204 to 622 ng/L (IQR); and with large PDA (n=11) 2410 ng/L median; 420 to 2770 ng/L (IQR). (p< 0.0001 for ANOVA; groupwise: p<0.05 for both no PDA vs. moderate and large PDA); Trend analysis suggested a strong association of BNP with size of PDA (p<0.001). Of 17 subjects with moderate to large PDA, pre and post-treatment (Ibuprofen; per standard protocol) data were obtained on 12 subjects. Pre-treatment BNP ranged from 111 to 5000 ng/L; post-treatment BNP decreased to 5.0 to 262 ng/L (p = 0.0005). Estimates of decision levels for treatment were made by examining dichotomized groups, i.e., no-tosmall vs. moderate-to-large and using receiver-operator characteristic (ROC) curve analysis yielding a value of 123 ng/L. BNP may obviate repeated echocardiography as follow up after treatment, or to monitor future course of respiratory distress secondary to PDA in PTN.

AB - Patent ductus arteriosus (PDA) is highly prevalent in pre-term neonates (PTN) and has been recognized as a neonatal co-morbidity. The purpose of this study was to determine if levels of brain (or B-type) natriuretic peptide (BNP), a peptide secreted by ventricular myocytes in response to volume or pressure overload, correlate with the size of the PDA. In a prospective design, 52 PTN (no PDA: n=24; PDA: n=28) were studied after obtaining parental consent. Those with genetic anomalies and congenital heart disease, except for PDA and patent foramen ovale, were excluded. Echocardiographic estimates offthe diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection the diameters of the PDA (or absence of PDA) were made concurrently with capillary blood collection for BNP assay. BNP levels in samples from PTN without PDA were 23.6 ng/L (median); 13.1 to 32.3 ng/L (IQR); initial samples (between days 3 and 7 of life) with small PDA (n=11), median 66.1 ng/L; 55.5 to 85.3 ng/L (IQR); with moderate PDA (n=6) median 284 ng/L; 204 to 622 ng/L (IQR); and with large PDA (n=11) 2410 ng/L median; 420 to 2770 ng/L (IQR). (p< 0.0001 for ANOVA; groupwise: p<0.05 for both no PDA vs. moderate and large PDA); Trend analysis suggested a strong association of BNP with size of PDA (p<0.001). Of 17 subjects with moderate to large PDA, pre and post-treatment (Ibuprofen; per standard protocol) data were obtained on 12 subjects. Pre-treatment BNP ranged from 111 to 5000 ng/L; post-treatment BNP decreased to 5.0 to 262 ng/L (p = 0.0005). Estimates of decision levels for treatment were made by examining dichotomized groups, i.e., no-tosmall vs. moderate-to-large and using receiver-operator characteristic (ROC) curve analysis yielding a value of 123 ng/L. BNP may obviate repeated echocardiography as follow up after treatment, or to monitor future course of respiratory distress secondary to PDA in PTN.

KW - B-type natriuretic peptide

KW - BNP

KW - Neonates

KW - Patent ductus arteriosus

KW - Point of care testing

KW - Premature infants

UR - http://www.scopus.com/inward/record.url?scp=80052665003&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052665003&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 131

EP - 137

JO - Annals of Clinical and Laboratory Science

JF - Annals of Clinical and Laboratory Science

SN - 0091-7370

IS - 2

ER -